Zynlonta (Loncastuximab tesirine-lpyl) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up log in
About MyLymphomaTeam
Powered By

Zynlonta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory large B-cell lymphoma who have tried at least two other systemic treatments. Zynlonta is also referred to by its drug name, loncastuximab tesirine-lpyl.

Zynlonta is a member of a class of drugs called antibody drug conjugates. Zynlonta is believed to work by destroying cancer cells.

How do I take it?
Prescribing information states that Zynlonta is administered intravenously every three weeks.

Zynlonta comes in the form of an injectable suspension.

Side effects
The FDA-approved label for Zynlonta lists common side effects including tiredness, weakness, skin rash, swelling, nausea, muscle or joint pain, high blood sugar, and changes in certain blood or laboratory test results.

Rare but serious side effects listed for Zynlonta include severe fluid retention, low blood cell counts, infection, skin reactions such as increased sensitivity to the sun, and fetal harm in pregnant women.

For more details about this treatment, visit:

Zynlonta — RxList

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of Use and Privacy Policy.
Already a Member? Log in